Amgen (NASDAQ:AMGN) Hits New 52-Week High on Earnings Beat

Shares of Amgen Inc. (NASDAQ:AMGN) hit a new 52-week high during trading on Wednesday after the company announced better than expected quarterly earnings. The stock traded as high as $356.52 and last traded at $352.5970, with a volume of 598987 shares trading hands. The stock had previously closed at $338.59.

The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The firm’s revenue was up 8.6% on a year-over-year basis. During the same period in the previous year, the firm posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.8%. This is a boost from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is currently 73.57%.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q4 results beat Street estimates — Amgen reported $5.29 EPS on $9.87B revenue, ahead of expectations, and cited volume growth and a lower tax rate as drivers of the upside; these beats support the company’s outlook and were the main near-term bullish catalyst. Amgen quarterly results beat Street estimates on higher sales, lower tax rate (Reuters)
• Positive Sentiment: Analyst upgrade/price-target lift — Leerink Partners raised its price target to $355 and kept an outperform view, signaling bullish conviction from some buy‑side analysts and providing upside to the stock. Leerink raises AMGN price target to $355 (Benzinga)
• Positive Sentiment: Pipeline and product momentum — Coverage notes highlight product-portfolio expansion and pipeline progress (new launches contributing to double‑digit revenue/EPS growth for 2025), which underpin management’s outlook. AMGN Q4 Deep Dive: Product Portfolio Expansion and Pipeline Progress Drive Outlook (Yahoo)
• Neutral Sentiment: Mixed analyst views — Some publications note divergent analyst opinions on valuation and near‑term risks, producing a mixed consensus that can limit a stronger rally. Analysts’ Opinions Are Mixed on These Healthcare Stocks (Globe and Mail)
• Negative Sentiment: Regulatory and LOE concerns — Analysis flags regulatory tensions around Tavneos and the challenge of mitigating loss‑of‑exclusivity (LOE) impacts, which increase execution risk and could pressure future growth if approvals or launches are delayed. Amgen: Strong Mitigation Of LOE Impact, Regulatory Tensions On Tavneos Emerge (Seeking Alpha)
• Negative Sentiment: Analyst caution on legacy erosion and execution — Some analysts (Citi/TipRanks) maintained or reiterated hold ratings, citing legacy-product erosion and execution risks that justify a more cautious stance and likely contributed to the stock pulling back. Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks (TipRanks)

Wall Street Analysts Forecast Growth

Several equities analysts have commented on AMGN shares. UBS Group increased their target price on Amgen from $380.00 to $390.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Leerink Partners upped their price objective on Amgen from $305.00 to $355.00 and gave the company an “outperform” rating in a research note on Wednesday. DZ Bank raised their price objective on shares of Amgen from $335.00 to $364.00 in a report on Monday, November 10th. Daiwa Capital Markets upped their price target on shares of Amgen from $310.00 to $370.00 and gave the company an “outperform” rating in a research report on Tuesday, November 18th. Finally, Truist Financial raised their price target on shares of Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research note on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $344.83.

Insiders Place Their Bets

In other news, SVP Nancy A. Grygiel sold 3,139 shares of the business’s stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the transaction, the senior vice president owned 7,225 shares in the company, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Murdo Gordon sold 6,879 shares of the stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the sale, the executive vice president owned 41,923 shares of the company’s stock, valued at approximately $14,120,924.09. This trade represents a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 10,908 shares of company stock worth $3,674,966. 0.69% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Sequoia Financial Advisors LLC lifted its position in Amgen by 2.3% in the third quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock valued at $45,334,000 after purchasing an additional 3,619 shares during the last quarter. Atlantic Union Bankshares Corp boosted its position in Amgen by 165.0% during the 2nd quarter. Atlantic Union Bankshares Corp now owns 10,643 shares of the medical research company’s stock valued at $2,972,000 after buying an additional 6,627 shares during the period. Davis Capital Management bought a new stake in Amgen in the 3rd quarter worth $1,841,000. D.A. Davidson & CO. increased its position in shares of Amgen by 2.6% in the third quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock valued at $68,590,000 after acquiring an additional 6,222 shares during the period. Finally, Global Wealth Management Investment Advisory Inc. raised its stake in shares of Amgen by 56.2% during the third quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock valued at $3,684,000 after acquiring an additional 4,699 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Trading Up 4.6%

The company has a quick ratio of 0.99, a current ratio of 1.28 and a debt-to-equity ratio of 5.45. The company has a market capitalization of $190.80 billion, a PE ratio of 27.30, a price-to-earnings-growth ratio of 3.03 and a beta of 0.46. The stock’s fifty day moving average price is $332.76 and its two-hundred day moving average price is $310.04.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.